NEW YORK, Dec. 21, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The global women's health market is increasingly competitive with, very few new active substances in the pipeline with the majority of research activity focuses on development of 'me-too' products, combinations and advanced re-formulations. The Women's Health Market Outlook to 2015 provides comprehensive coverage of the global women's health market, incorporating an overview of key diseases specific to women and a detailed epidemiological analysis. It makes a wide-ranging analysis of both currently marketed products and those in the product pipeline and gives an assessment of the leading players in the market.
Scope of this research
- Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive market changes.
- Compare the franchises of the leading companies in global women's health market, and understand how the market share of these companies will change.
- Assess key pipeline products by indication, ongoing trials, recent product launches and key developments in R&D.
- Identify the challenges confronted by leading players, and understand how recent events will impact the performance of leading products.
- Access forecasts of the leading marketed and pipeline products through to 2015.
Research and analysis Highlights
The global women's health market was valued at $20.4bn at a Y-o-Y growth of 1%, the US dominated this market. Collectively, the top five EU markets represented the second largest women's health market with 2009 sales of $3.5bn and a market share of 17.3%.
Hormonal contraceptives with 2009 sales of $9bn represented 44.3% of the market and remained the major therapeutic class in the women's health market. Bayer's Yaz and Yasmin (drospirenone + ethinyl estradiol) were the largest selling drugs in this category accounting for a market share of 24.3%.
The top 10 generic players in the global women's health market represented 68.3% of the total generic market in 2009. J&J followed by Ferring remained the market leaders in the generic women's health market.
Key reasons to purchase this research
- What will be the major growth indications and the accompanying growth drivers in the women's health market over the next 6 years?
- Which companies led the women's health market in 2009?
- Which products will be the future growth drivers for the women's health market?
- Which therapeutic categories are forecast to have the highest levels of commercial potential over the period 2009–15?
- Which companies are best positioned to succeed in the women's health market over the period 2009–15?
To order this report:
Intl: +1 805-652-2626